| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biogen Inc. | 4 | Q4 2015 | 4.2% |
| Celgene Corporation | 4 | Q4 2015 | 4.1% |
| Gilead Sciences, Inc. | 4 | Q4 2015 | 4.1% |
| Medtronic, Inc. | 4 | Q4 2015 | 3.7% |
| Abbott Laboratories | 4 | Q4 2015 | 3.3% |
| Regeneron Pharmaceuticals, Inc. | 4 | Q4 2015 | 3.0% |
| Amgen Inc. | 4 | Q4 2015 | 3.0% |
| Illumina, Inc. | 4 | Q4 2015 | 2.7% |
| UnitedHealth Group Incorporated | 4 | Q4 2015 | 2.3% |
| Stryker Corporation | 4 | Q4 2015 | 2.2% |
View Bellevue Asset Management AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Auris Medical Holding AG | February 14, 2018 | 2,169,625 | 4.5% |
View Bellevue Asset Management AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-14 |
| 13F-NT | 2023-08-14 |
| 13F-NT | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-11 |
| 13F-NT | 2022-05-13 |
| 13F-NT | 2022-02-10 |
| 13F-NT | 2021-11-12 |
View Bellevue Asset Management AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.